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ABSTRACT
Hepatitis E virus (HEV) infection is a major cause of acute hepatitis but also provokes chronic
infection in immunocompromised patients. Although the pathogenesis and treatment outcome
involve complex interplay between the virus and host, the nature of adaptive responses of HEV
to the host immune system remain obscure at best. In this study, we used large-scale
proteomic bioinformatics to proﬁle characteristic mutations in human HEV isolates associated
to ribavirin treatment failure, chronic hepatitis, hepatic failure or altered immunoreactivity. The
prevalence of speciﬁc mutations was examined in a large number of protein sequences of
ORF1 and ORF2 regions of the 3 major human-derived HEV genotypes (1, 3 and 4). By
analyzing potential B, CD4C and CD8C T cell epitopes, we found that many of these mutations
overlap with the predicted epitopes and are frequently present among the 3 HEV genotypes.
These overlapping mutations mediate reduced antigenicity. Finally, by delineation of
diversiﬁcation and evolution of the underlying epitopes, we observe that most of these
variants apparently evolved earlier in genotype 1 when compared with genotypes 3 and 4.
These results indicate that HEV is under substantial evolutionary pressure to develop mutations
enabling evasion of the host immune response and resistance to antiviral treatment. This
indicates the existence of an ongoing evolutionary arms race between human immunity,
antiviral medication and HEV.
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Introduction
Hepatitis E virus (HEV) is a non-enveloped, single-
stranded positive sense RNA virus which mainly
infects the liver.1 It causes over 3 million acute cases
and 57,000 deaths every year.2 Although 8 HEV geno-
types are now recognized, there are 4 well-deﬁned gen-
otypes infecting humans, including genotype 1, 2, 3
and 4. Genotypes 1 and 2 are found only in humans
and are responsible for most cases of infection in the
developing countries. Genotypes 3 and 4 circulate in
several animals (e.g. pigs, wild boars and deer) and are
the main cause of sporadic infection in the developed
countries.3,4 Although no FDA-approved treatment is
available, pegylated interferon-a (PEG-IFN-a) or riba-
virin has been used as off-label treatment of some
cases of HEV infection.5,6
As an RNA virus, HEV possesses a high mutation
rate. It was indirectly estimated from clinical isolates that
the mutation rate of HEV was »1.5 base substitutions
per site per year, which is quite similar to that reported
for hepatitis C virus (HCV).7 The viral RNA-dependent
RNA polymerase (RdRp), which lacks the proof-reading
capacity, is an important factor contributing to the high
rate of mutations in the HEV genome.8 Furthermore, the
selection pressure imposed by the host immune
responses may also contribute to the variability of HEV
genome. Recently, studies have hinted at the acquisition
by the HEV genome of certain mutations associated with
ribavirin treatment failure, chronic hepatitis, hepatic fail-
ure and reduced immunoreactivity.9 The observation
that different mutations change the HEV proteome with
respect to not only the therapeutic response but also the
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immunoreactivity highlights the importance of studying
HEV mutations and their effects on the host immune
responses.
Only limited knowledge is available on the contribu-
tion of HEV genome variants toward susceptibility, path-
ogenesis and therapeutic responses. To elucidate these
processes, we have used a large-scale proteomic bioinfor-
matics to proﬁle human HEV characteristic mutations.
In the present study, we have comprehensively investi-
gated the proteomic variation of the open reading frame
1 (ORF1) and ORF2 regions among the major HEV gen-
otypes 1, 3 and 4, by retrieving a large data set of HEV
sequences. We ﬁrst mapped the presence and abundance
of the mutations related to ribavirin treatment failure,
chronic hepatitis, hepatic failure or reduced immunore-
activity. Furthermore, we examined the overlap of these
mutations with predicted B cell, CD4C and CD8C T cell
epitopes, and assessed their antigenicity. Interestingly,
we have observed that these overlapped mutations
evolved earlier in genotype 1 when compared with geno-
type 3 and 4. Thus, the acquisition and evolution of these
characteristic mutations may help the virus to evade host
immune response, develop resistance to antiviral treat-
ment, and facilitate its adaptation in human population.
Results
Identiﬁcation of HEV characteristic mutations
Several HEV variants were previously reported both in
vitro and in vivo. Using a combination of phrases/key-
words in PubMed (Table S1), we explored clinical and in
vitro data reporting mutations within the ORF1 and
ORF2 of HEV. In our analysis, 20 mutations (Table S2)
were identiﬁed in these regions, 17 in ORF1 and 3 in
ORF2 (Fig. 1). Among these mutations, one was related
to chronic hepatitis, 9 with hepatic failure, 8 with ribavi-
rin treatment failure, and 2 with altered immunoreactiv-
ity (Table S2).
Frequency of mutations within ORF1 and ORF2
To evaluate the relevance of these reported characteristic
mutations, we ﬁrst evaluated their presence in the circu-
lating strains based on the HEV sequences deposited in
the GenBank. We have searched the 4 main genotypes
identiﬁed from the human host. However, limited
sequences are available for genotype 2. Thus, we
retrieved 57 ORF1, 51 ORF2 (genotype 1), 131 ORF1,
131 ORF2 (genotype 3) and 99 ORF1, 96 ORF2
Figure 1. (A). Identiﬁed mutations of ORF1 and ORF2 regions of HEV. The number within the box represents the amino acid position; the
letter(s) above the box refer to the wild type amino acid, and the letter below the box are relevant mutations reported in previous stud-
ies. (Met: methyltransferase; Y: Y-domain; HVR: hypervariable regions; Hel: RNA helicase; RdRP: RNA-dependent RNA polymerase; C: cap-
sid protein) (B). The prevalence of mutations within HEV genotype 1 (n D 81), 3 (n D 182) and 4 (n D 143). Amino acid diversity was
measured as the proportion of sequences that varies from the consensus sequence.
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(genotype 4) of HEV sequences (retrieved in January
2017). The selected sequences represent all major geno-
types (1, 3 and 4). The full-length sequences used in this
study based on each ORF and genotype are provided in
Table S3.
After removal of closely related and redundant
sequences, 406 full length ORF1 and ORF2 sequences
were ﬁnally selected for further analysis. Table 1,
Table S2 and Fig. 1 show the number of all possible and
experimentally conﬁrmed amino acid variants and fre-
quency of their variation for each HEV genotype. The
number of variants found in ORF1 region was higher (17
variants) than that of ORF2 region (3 variants). Out of
17 variants in ORF1, 8 were related to hepatic failure;
one with chronic hepatitis; and 8 with ribavirin treat-
ment failure. While in ORF2, one variation was associ-
ated with hepatic failure and 2 with immunoreactivity.
When analyzing HEV genotypes, it was revealed that
genotype 1 possesses a higher number of mutations (8)
with considerable frequency when compared with geno-
type 3 and 4 which possesses only 6 and 3 mutations,
respectively (Table 1 and Fig. 1B). This observation fur-
ther suggests the high level of polymorphism in HEV
genotype 1.
Mutations within genotype 1, 3 and 4
In genotype 1, 9 out of 17 reported mutations
(V1213A, Y1320H, K1383N, D1384G, K1398N,
C1483W, N1530T, Y1587F, G1634R) in ORF1 and
one (P259S) out of 3 in ORF2, were found to be con-
served (i.e. not present in our analyzed sequences),
while others have shown considerable variations
(Table 1). Among these variable mutations, T735I
and G1634R/K were observed to be frequent among
all selected genotype (1, 3 and 4). Another mutation
(A317T) was found in 2 genotypes (1 and 3). Four
mutations (ORF1 D 2; ORF2 D 2) reached the fre-
quency of > 90% (Table 1, Fig. 1B). Among these, 2
mutations were related to ribavirin treatment failure
[G1634K/R (ORF1; genotype 1, 3, 4) and Y1587F
(ORF1; genotype 4)] and 2 were associated with
altered immunoreactivity [L477T (ORF1; genotype 1,
3) and L613T (ORF1; genotype 1, 3)].
In genotype 3, we found that the reported mutation
sites [13 in ORF1 (F179S, L1110F, V1120I, Y1320H,
K1383N, D1384G, K1398N, F1439Y, V1479I, C1483W,
N1530T, Y1587F, G1634K) and one (P259S) in ORF2]
were conserved (i.e., not present in our analyzed sequen-
ces) (Table 1, Fig. 1B). Mutations of ORF1, i.e., V1213A
and G1634R, were found with a considerable frequency
in genotypes 3 and 4. The most important variants were
A317T and V1213A which showed a high prevalence in
genotype 3. Four mutations approached a frequency of
> 90%, where one was related to chronic hepatitis
(V1213A), one with ribavirin treatment failure (G1634R)
and 2 with immunoreactivity (L477T, L613T) (Table 1,
Fig. 1B).
In genotype 4, 13 sites in ORF1 (F179S, A317T,
L1110F, V1120I, V1213A, Y1320H, K1383N, K1398N,
D1384G, F1439Y, V1479I, C1483W, N1530T) and 3 in
ORF2 (P259S, L477T, L613T) were found to be con-
served. Mutation Y1587F was frequent in genotype 4.
Two mutations reached the frequency of > 90%
(Y1587F, G1634R) (Table 1, Fig. 1B). Both mutations
have been reported to be related to ribavirin treatment
failure (Y1587F, G1634R).
Mutations as a missense SNPs and their effects
on protein structural stability
In our analysis, 4 in silico SNP prediction algorithms
were used to predict the selected mutations as neutral
or deleterious. According to predicted results, most of
the selected mutations with high prevalence in HEV
infected papulation are deleterious (Table S5). Next,
most of these mutations are predicted to cause destabi-
lization of the protein as calculated using 3 web servers
(Table S6), suggesting the importance of these muta-
tions. Because the crystal structure of HEV ORF2
(2ZTN-amino acid 129–606) is available (Fig. 3A). We
have modeled the effect of 2 mutations that are located
Table 1. All possible and experimentally conﬁrmed (in vivo and in
vitro) mutations and their prevalence in the major HEV genotypes
(1, 3, 4). Different colors indicate the mutations related to ribavi-
rin treatment failure (yellow), chronic hepatitis (purple), hepatic
failure (red) or altered immunoreactivity (blue).
Percentage
Mutations GT1 ORF1 (57) GT3 ORF1 (131) GT4 ORF1 (99)
ORF1 F179S 16 (28%) 0 0
A317T 28 (49%) 128 (98%) 0
T735I 26 (46%) 60 (46%) 43 (43%)
L1110F 35 (61%) 0 0
V1120I 38 (67%) 0 0
V1213A 0 125 (95%) 0
Y1320H 0 0 0
K1383N 0 0 0
D1384G 0 0 0
K1398N 0 0 0
F1439Y 9 (16%) 0 0
V1479I 54 (95%) 0 0
C1483W 0 0 0
N1530T 0 0 0
Y1587F 0 0 96 (97%)
G1634R 0 128 (98%) 96 (97%)
G1634K 54 (95%) 0 0
GT1 ORF2 (51) GT3 ORF2 (131) GT4 ORF2 (96)
ORF2 P259S 0 0 0
L477T 46 (90%) 127 (97%) 0
L613T 46 (90%) 125 (95%) 0
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within this region on structural stability of the protein.
We found that both P259S (Fig. 3B) and L477T
(Fig. 3C) are predicted to cause destabilization of
ORF2 protein.
Overlap of characteristic mutations within the
predicted B cell, CD4C and CD8C T cell epitopes
The consensus sequence of ORF1 and ORF2 of geno-
types 1, 3 and 4 (respectively) was used to predict B cells,
major histocompatibility complex class I (MHCI) and
class II (MHCII) T cell epitopes using IEDB, ProPred-1
and ProPred, respectively.10-12 In case of MHCI and II,
epitope’s binding to maximum number of alleles and
binding capacity of < 500 mM were selected. The pre-
dicted epitopes were further conﬁrmed by BLASTp13 to
avoid considering the epitopes that have a homology
with human proteins.
The predicted epitopes were then evaluated for the
presence or absence of the reported mutations (Table 1).
We found that many of these characteristic mutations
reported in ORF1 and ORF2 regions overlap with the
predicted epitopes and were also frequently observed
among selected HEV genotypes (1, 3 and 4) (Table 2 and
Table 3). In our analysis, all epitopes possessing muta-
tions that are present in our analyzed HEV sequences
were considered. Table 2 and Table 3 show mutations in
the predicted epitopes of ORF1 and ORF2 (consensus
genotype 1, 3 and 4) against B cells, MHC-I and MHC-II
T cells. It was observed that ORF1 and ORF2 of genotype
1 possess more epitopes with reported mutations when
compared with genotype 3 and 4 (Table 2 and 3). Most
of these overlapped mutations were related to hepatic
failure (HF), followed by ribavirin treatment failure
(RTF), altered immunoreactivity (AI) and chronic hepa-
titis (CH) (HF>RTF>AI>CH).
Figure 2. Antigenicity difference between wild-type and mutated T cell (MHCI and MHCII) (A) and B cell epitopes (B).
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Alteration of epitope antigenicity by characteristic
mutations
We hypothesize that HEV may alter its epitopes by
acquiring mutations to evade the immune recognition by
both B and T cells.14 The online tool VaxiJen15 was used
to detect the effect of each mutation on the antigenicity
of the epitopes (wild type and mutation containing
epitopes) (Table 2 and Table 3). Interestingly, in many
cases, mutated epitopes have a reduced antigenicity
when compared with the wild-type epitope (Table 2,
Table 3, and Fig. 2). Some mutated epitopes have a sus-
tained antigenicity, while only few mutated epitopes
have an increased antigenicity. These ﬁndings suggest
that most of the reported mutations within predicted
epitopes have a reduced antigenicity. Consequently, they
are less recognized by both B and T cells and thus,
decreasing the effective roles of the adaptive immune
cells to clear the infections.
Evolution of the characteristic mutations
To visualize the mutation evolution within the predicted
epitopes of each genotype, a heat map was generated for
each reported mutation (Fig. 4). The concept of evolving
mutations among the HEV genotypes within antigenic
area will be helpful in determining their role in both
immune and therapeutic responses. Different trends of
evolving mutations have been observed in our analysis.
The mutations A317T, T735I, L1110F, V1120I, V1479I
and G1634K which were frequently observed in genotype
1 ORF1 have an evolving period of 3 y (1998–2001), 6 y
(1998–2003), 8 y (1992–1999) 7 y (1992–1998), 5 y
(1983–1987) and 4 y (1983–1986), respectively (Fig. 4
and Fig. 5). A commonly observed variation in all
selected genotypes (1, 3 and 4), i.e., T735I, was found to
be evolved earlier in ORF1 of genotype 1 (1998–2003)
when compared with genotype 3 and 4. Another com-
mon variation G1634K/R evolved earlier in ORF1 of
genotype 1 (1983–1986) as compared with genotype 3
(1993–1997) and genotype 4 (1995–1998) (Fig. 4 and
Fig. 5). Similarly, the mutations in ORF2 (L477T and
L613T) appear to evolve earlier in genotype 1 compared
with genotype 3 (Fig. 4 and Fig. 5). These data collec-
tively indicate an earlier acquisition of several character-
istic mutations in genotype 1 as compared with genotype
3 and 4.
Discussion
Ribavirin monotherapy has been widely used for treat-
ment of chronic hepatitis E.5 It is in general very effec-
tive. However, for a subset of patients, ribavirin
treatment fails.16,17 Mutations in the viral polymerase
have been noted before or during therapy in these
patients.18 Furthermore, many mutations related to
hepatic failure, chronic hepatitis and immunoreactivity
have also been reported, conferring the importance of
these mutations in HEV pathogenesis and treatment
responses. In support of this, several studies have shown
that proteomic variations in certain epitopes that are
Figure 3. The effects of mutations (P259S, L477T) on the struc-
tural stability of ORF2 region of HEV predicted by DUET web
server. Mutations are shown in blue color ribbon. (A) Crystal stru-
ture without mutation of ORF2 (2ZTN-amino acid 129–606). (B).
P259S; feature: distabilizing; secondary structure: loop or irregu-
lar. (C). L477T; feature: distabilizing; secondary structure:
extended b-strand.
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associated with these mutations can critically inﬂuence
the outcome of the immune responses.19 These antigenic
variations have been observed among HEV strains using
genotype- and strain-speciﬁc monoclonal antibodies.20
Even though several studies have reported frequencies of
mutations in the HEV genome, the global prevalence of
these characteristic mutations has not been comprehen-
sively studied. Thus, this study has evaluated the HEV
ORF1 and ORF2 variability in major genotypes (1, 3 and
4) by a systematic retrieval of human-derived HEV
sequences. Furthermore, important co-occurrence of B
and T cell (CD4C and CD8C) epitope mutations was
revealed, suggesting adaptation of viruses to escape
immune surveillance.
By exploring the intra-genotypic diversity from rep-
resentative human HEV genotypes, we have demon-
strated that genotype 1 produces the largest number of
intra-genotypic variants (Table 1). These variants were
found to be evolved with a period of on average »4 y
but varied from 3 to 5 y in the human population
(Fig. 4 and Fig. 5). Surprisingly, some reported muta-
tions, including Y1320H, K1383N, D1384G and
Table 2. Antigenicity evaluation of wild-type and mutated epitopes. The effect of mutations on the antigenicity (threshold level D 0.4)
of T cell predicted epitopes (MHCI and MHCII). Bold letters (one-letter amino acid code) represent mutations within the predicted
epitopes.
Region/ Genotype Epitopes name Position Wild-type epitope Antigenicity Mutated epitope Antigenicity
MHCI
ORF1/GT1 T1 F179S MFRHGMTRL 0.1 MF/SRHGMTRL 0.2
T2 T735I ATPTPAAPL 0.2 ATPT/IPAAPL 0.2
T3 L1110F TTSRVLRSL 0.4 TTSRVL/FRSL ¡0.6
T4 F1439Y FYGDAFDDT 0.2 FYGDAF/YDDT 0.2
T5 G1634K AVSDFLRGL 0.4 AVSDFLRG/KL ¡0.6
ORF2/GT1 T6 L613T SALALLEDL 0.3 SALALLEDL/T 0.5
MHCII
ORF1/GT1 T7 A317T FHAVPAHIW 0.5 FHAVPA/THIW ¡0.7
T8 T735I IPSRAATPT 0.2 IPSRAATPT/I 1
T9 V1120I FWGEPAVGQ 0.2 FWGEPAV/IGQ 0.2
T10 V1479I LGLECAVME 0.8 LGLECAV/IME 0.7
T11 G1634K LRGLTNVAQ 0.7 LRG/KLTNVAQ 0.7
ORF2/GT1 T12 L477T WLSLLAAEY 1.1 WLSLL/TAAEY 1.7
MHCI
ORF1/GT3 T13 V1213A VIVNNFFLV 0.1 VIVNNFFLV/A ¡0.1
T14 G1634R LGLAVCDFL 0.2 LG/RLAVCDFL ¡0.3
MHCII
ORF1/GT3 T15 V1213A LVGGEVGHH 1.1 LV/AGGEVGHH 1
T16 G1634R LGLAVCDFL 0.2 LG/RLAVCDFL ¡0.3
ORF2/GT3 T17 L477T WLSLLAAEY 1.1 WLSLL/TAAEY 1.7
T18 L613T VLEDLIDYP 0.4 VLEDL/TIDYP ¡0.17
MHCI
ORF1/GT4 T19 T735I AEADTPVAV 0.2 AEADT/IPVAV 0.1
T20 V1213A REVGISDAI 0.8 REVGISDV/AI 0.7
T21 G1634R SERAEQLRL 0.3 SEG/RAEQLRL 0.3
MHCII
ORF1/GT4 T22 T735I VATDVPPPA 0.4 VAT/IDVPPPA 0.1
T23 V1213A VIVNNFFLS 0.03 V/AIVNNFFLS 0.02
Table 3. Antigenicity evaluation of wild-type and mutated epitopes. The effect of mutations on the antigenicity (threshold level D 0.4)
of predicted B cells epitopes. Bold letters (one-letter amino acid code) represent mutations within the predicted epitopes.
Region/Genotype Epitopes name Position Wild-type B cell epitopes Antigenicity Mutated B cell epitopes Antigenicity
B1 F179S FRHGMTRLY 0.1 F/SRHGMTRLY 0.1
ORF1/GT1 B2 T735I TPAAPLPPP 0.1 T/IPAAPLPPP 0.1
B3 L1110F TTSRVLRSL 0.1 TTSRVL/FRSL 0.01
B4 V1120I WGEPAVGQK 0.8 WGEPAV/IGQK 1
B5 F1439Y FYGDAFDDT 0.2 FYGDAF/YDDT 0.2
B6 G1634K SDFLRKLTN 0.1 SDFLRG/KLTN ¡0.1
ORF2/GT1 B7 L477T SLTAAEYDQ 1.1 SLL/TAAEYDQ 1.0
B8 L613T LLDYPARAH 0.4 L/TLDYPARAH 0.4
ORF1/GT3 B9 T735I LPHPTPPVS 0.5 LPHPT/IPPVS 0.6
B10 G1632R ERAEQLRLA 0.1 ERAEQLG/RLA 0.1
ORF2/GT3 B11 L477T SLTAAEYDQ 1.1 SLL/TAAEYDQ 0.5
B12 L613T LIDYPARAH 0.5 L/TIDYPARAH 0.4
ORF1/GT4 B13 V735I TPVAVDVPP 0.5 TPVAV/IDVPP 0.6
B14 Y1587F CGLKLKVDY 0.7 CGLKLKVDY/F 1.7
B15 G1634R KNWGPGSEG 1.8 KNWGPGSEG/R 1.7
6 A. IKRAM ET AL.
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K1398N (related to ribavirin treatment failure) and
C1483W, N1530T and P259S (related to hepatic fail-
ure), were hardly present in our retrieved large set of
sequences, suggesting their insigniﬁcance. In contrast, 2
mutations T735I (related to hepatic failure) and
G1634R (related to ribavirin treatment failure) were
found in all selected genotypes (1, 3 and 4) with a con-
siderably high frequency. Among these mutations,
Figure 4. A heat map showing the evolvment of mutations with years. Mutations 1 D F179S, 2 D A317T, 3 D T735I, 4 D L1110F, 5 D
V1120I, 6 D V1213A, 7 D Y1320H, 8 D K1383N, 9 D D1384G, 10 D K1398N, 11 D F1439Y, 12 D V1479I, 13 D C1483W, 14 D N1530T,
15 D Y1587F, 16 D G1634R, 17 D G1634K, 18 D P259S, 19 D L477T, 20 D L613T. Each box represents the sequence of ORF 1 or ORF2,
from genotype 1, 3 or 4 in a particular year. Red colored boxes represent the mutations related to hepatic failure mutations; purple to
chronic hepatitis; yellow to ribavirin treatment failure; and blue to altered immunoreactivity. The year of deposition of each sequence is
mentioned in the arrow below the heat map.
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G1634R was identiﬁed in patients as a baseline muta-
tion that effects ribavirin treatment response.21 This
mutation was also observed in a patient with chronic
hepatitis E, experiencing ribavirin treatment failure with
a completely resistant phenotype.16 However, the exact
clinical relevance of such mutations in ribavirin treat-
ment failure is uncertain since ﬁndings from in vitro
studies show that some of these mutations facilitate
HEV replication but paradoxically seem to increase
ribavirin sensitivity,16 thus requiring further investiga-
tion. Furthermore, effective new antiviral therapy is
needed for HEV patients with ribavirin treatment fail-
ure.22 Two immunoreactivity-related mutations (L477T
and L613T) were mainly found in genotype 1 and 3
highlighting the role of such mutations in affecting host
immune response (Table 1).
To investigate the implication of these characteristic
mutations in the host immune response, we have proﬁled
their overlap with predicted B and T cell epitopes. We
found that the hotspot sites where mutations and pre-
dicted epitopes overlap are frequently present among
many HEV genotypes (Table 1 and Fig. 2). The subse-
quent analysis of these mutations showed that this over-
lap mostly decreases and in few cases, sustains or
enhances the antigenicity of the mutated epitopes
(Table 2, Table 3 and Fig. 2). Experimental studies have
demonstrated that only antibodies recognizing confor-
mational epitopes are neutralizing, and the aa residues
Leu477 and Leu613 in the capsid protein are important
in forming a neutralization-sensitive epitope representing
the importance of these mutations in epitope deforma-
tion.23 In patients, HEV-speciﬁc T cells target relatively
conserved HEV peptides, and those are predominantly
located in the ORF2 capsid protein. The T-cell responses
persist over years after resolution of HEV infection, sug-
gesting the role in both clearance of primary infection
and protective immune response against secondary infec-
tion.24 Based on our study, we propose a model of
immune evasion by HEV (Fig. 6). In this model, mutated
epitopes will result in escape recognition by B and T cells.
Furthermore, we have mapped the evolution of these
mutations in all selected genotypes. We found that most
of the overlapped mutations are more abundantly present
in genotype 1 as compared with genotype 3 and 4. Inter-
estingly, the common mutations evolved earlier in geno-
type 1 than genotype 3 and 4.
In summary, our study represents a comprehensive
analysis of the characteristic mutations in the major
HEV genotypes. Some of these mutations overlap with
predicted B and T cell epitopes that are expected to affect
the antigenicity. We further revealed the evolution of
these mutations among the 3 major genotypes. These
results indicate that HEV is under substantial evolution-
ary pressure to develop mutations enabling evasion of
the host immune response and resistance to antiviral
treatment. This indicates the existence of an ongoing
evolutionary arms race between human immunity, anti-
viral medication and the HEV.
Figure 5. Evolution period of overlapped mutations. Each bar represents the evolving period (years) of each mutations.
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Material and methods
Data collection
A database on reported mutations within the ORF1
and ORF2 regions of HEV is currently not available.
We reviewed earlier studies (through January 2017),
using a combination of the keywords that are listed in
Table S1, and evaluated mutations in HEV-infected
individuals, as well as in HEV replicons. These studies
were searched from the PubMed (ncbi.nlm.nih.gov/
pubmed), EMBASE, and Cochrane Library databases.
Retrieval of sequences
We retrieved 57 ORF1, 51 ORF2 (genotype 1), 131
ORF1, 131 ORF2 (genotype 3) and 99 ORF1, 96 ORF2
(genotype 4) of HEV protein sequences from the Gen-
Bank25 (accessed on January 2017). The selected protein
sequences represent all major genotypes (1, 3 and 4).
The GenBank accession numbers of HEV protein
sequences used in this study against each ORF and geno-
type are provided in Table S3. The sequences were
trimmed manually and analyzed using the reference pro-
tein sequences of selected genotypes [AF185822 (geno-
type 1), AB291960 (genotype 3), AB200239 (genotype
4)]. Different quality control measures were performed
for the sequences, and many sequences were disqualiﬁed
for further analysis based on the following 2 conditions:
(a) if the sequence derived from a non-human host; and
(b) if the sequence was a clonal sequence from the same
patient. Sequences were also annotated by the year of
sampling. In some cases where the source did not
provide the sampling year, we used the submission date
to the GenBank as the sampling year.
Consensus sequence and mutations analysis
The HEV ORF1 and ORF2 sequences were aligned using
ClustalW, BioEdit and CLC Workbench 7 (http://www.
clcbio.com). A consensus analysis for each HEV geno-
type was performed to observe the presence or absence
of mutation at each site. These mutations were selected
on the basis of published data reporting all experimen-
tally proven mutations (in vitro and in vivo). The preva-
lence of each mutation was then measured within the
selected regions (ORF1 and ORF2) of each genotype (1,
3 and 4).
Analysis of mutations as a missense SNPs and their
effects on structural stability
To validate selected mutations as missense SNPs in
ORF1 and ORF2 regions of HEV genotype 1, 3 and 4,
computational analysis was performed using 4 tools
PROVEAN (Protein Variation Effect Analyzer),26 nsSNP
analyzer,27 SNPs & GO and PMUT.28 These tools
describe missense SNPs as damaging or neutral to func-
tion and structure. To predict the change in protein sta-
bility due to these SNPs, DUET,29 I-Mutant version
2.0,30 and STRUM31 web servers were used. As an input
in I-Mutant and STRUM servers, FASTA sequences of
ORF1, ORF2 regions of selected genotypes were used.
PDB ﬁles of 3D structures (2ZTN) of ORF2 were used as
an input in DUET web server.
Figure 6. Possible mechanisms of immune evasion by hepatitis E virus. Main routes by which HEV mutations may result in evasion of the
host immune responses. Mutated epitopes presented by antigen presenting cells, B and T cells will results in escape recognition of the
epitopes.
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Prediction of the B and T cell epitopes and
comparison with the host proteome
Nine-mer B cell epitopes were predicted against HEV
genotype (1, 3 and 4) from their consensus sequence by
using online tool, the Immune Epitope Database
(IEDB).32 Similarly, 9-mer T cell epitopes (MHC class I
and II), following the same criteria as B cell epitopes,
were predicted by online T cell epitope prediction tools,
including ProPred-I (MHCI) and ProPred (MHCII).33,34
ProPred-I and ProPred identify and predict 47 types of
MHCI and 57 types of MHCII allele speciﬁc binding
peptides in a provided protein, respectively.33,34 The pre-
dicted T cell epitopes were also conﬁrmed by IEDB
tool.35 The selected epitopes were analyzed for compari-
sons with the human proteome using the Protein Blast
program (BLASTp).13 This was performed to validate
that these epitopes will not trigger an autoimmune
response.
Overlapping sites of mutations and predicted
epitopes
A comprehensive exploration was performed to ﬁnd out
any reported mutations positioned in a predicted epi-
tope. Predicted B cells and T cells epitopes were mapped
to ORF1 and ORF2 regions that contain most of the
reported mutation sites. Finally, the incidence of these
overlapped mutations was determined among the
selected genotypes (1, 3 and 4) by using percentage
formula.
Prediction of antigenicity of epitopes
To investigate the antigenic properties of epitopes before
and after mutations, VaxiJen tool was used.15 The analy-
sis was performed to ﬁnd out whether these mutations
lead to decreased, enhanced or sustained antigenicity of
the speciﬁc epitopes.
Evolutionary analysis of mutations
To visualize the evolution of amino acid mutation related
to chronic hepatitis, hepatic failure, ribavirin treatment
failure or immunoreactivity within each genotype, a heat
map was developed by GraphPad Prism version 7
(GraphPad Software, La Jolla California, USA) to calcu-
late the number of amino acid and the isolation year dif-
ferences between 3 individual genotypes. Isolation years
were extracted from the strain-annotated information.
The difference values were added into a matrix where
the y-axis represents the isolation year differences and
the x-axis represents the amino acid differences.
Abbreviations
AI Altered immunoreactivity
CH Chronic hepatitis
HCV Hepatitis C virus (HCV)
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